Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
Total Valuation
Relmada Therapeutics has a market cap or net worth of $23.50M. The enterprise value is $362.83K.
Market Cap$23.50M
Enterprise Value$362.83K
Share Statistics
Relmada Therapeutics has 33,191,624 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,191,624
Owned by Insiders5.13%
Owned by Institutions4.48%
Financial Efficiency
Relmada Therapeutics’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -236.14%.
Return on Equity (ROE)-2.25
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)-236.14%
Return on Capital Employed (ROCE)-2.36
Revenue Per Employee0.00
Profits Per Employee-4.70M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relmada Therapeutics is -0.20. Relmada Therapeutics’s PEG ratio is <0.01.
PE Ratio-0.20
PS Ratio0.00
PB Ratio0.18
Price to Fair Value0.44
Price to FCF-0.25
Price to Operating Cash Flow-0.25
PEG Ratio<0.01
Income Statement
In the last 12 months, Relmada Therapeutics had revenue of 0.00 and earned -79.98M in profits. Earnings per share was -2.65.
Revenue0.00
Gross Profit0.00
Operating Income-83.89M
Pretax Income-79.98M
Net Income-79.98M
EBITDA-79.98M
Earnings Per Share (EPS)-2.65
Cash Flow
In the last 12 months, operating cash flow was -56.79M and capital expenditures 0.00, giving a free cash flow of -56.79M billion.
Operating Cash Flow-56.79M
Free Cash Flow-56.79M
Free Cash Flow per Share-1.71
Dividends & Yields
Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.11
52-Week Price Change-76.33%
50-Day Moving Average0.51
200-Day Moving Average1.36
Relative Strength Index (RSI)56.94
Average Volume (3m)705.49K
Important Dates
Relmada Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Relmada Therapeutics as a current ratio of 4.45, with Debt / Equity ratio of 0.00%
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.00
Net Debt to EBITDA0.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relmada Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relmada Therapeutics EV to EBITDA ratio is -0.15, with an EV/FCF ratio of -0.23.
EV to Sales0.00
EV to EBITDA-0.15
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23
Balance Sheet
Relmada Therapeutics has $27.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$27.06M billion.
Cash & Marketable Securities$27.06M
Total Debt$0.00
Net Cash-$27.06M
Net Cash Per Share-$0.82
Tangible Book Value Per Share$1.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Relmada Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside40.85% Upside
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast19.21%